Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Related Content:

University of Chicago Medicine Comprehensive Cancer CenterOncLive TVImmunotherapy in MelanomaMelanoma & Skin CancerImmuno-Oncology
Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer
Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs
Dr Garmezy on Findings From the Duravelo-1 Trial in Metastatic Urothelial Carcinoma